Advice
Medicine discontinued
In September, 2024, the Marketing Authorisation for pralsetinib (Gavreto) was discontinued.
Medicine details
- Medicine name:
- pralsetinib (Gavreto)
- SMC ID:
- SMC2496
- Indication:
As monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 13 March 2023
Additional notes
In September, 2024, the Marketing Authorisation for pralsetinib (Gavreto) moved from Roche to BluePrint Medicines. BluePrint Medicines will discontinue global marketing and development of pralsetinib in all territories (excluding US and Greater China).